(2023). IncidencePrevalence: An R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5717.
(2023). Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. Eclinicalmedicine, 58, 101932. http://doi.org/10.1016/j.eclinm.2023.101932.
(2022). Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom. Nat Commun, 13, 7167. http://doi.org/10.1038/s41467-022-34668-w.
(2022). Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. Bmj, 379, e071594. http://doi.org/10.1136/bmj-2022-071594.
(2022). Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf, 31, 495-510. http://doi.org/10.1002/pds.5419.
(2022). Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. Bmj, 376, e068373. http://doi.org/10.1136/bmj-2021-068373.
(2020). Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keaa771.
(2020). Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. http://doi.org/10.1016/s2665-9913(20)30276-9.